Demonstration of a rational strategy for human prostate cancer gene therapy.

[1]  F. Marshall,et al.  Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. , 1995, Human gene therapy.

[2]  S. Rosenberg,et al.  Immunotherapy and gene therapy of cancer. , 1991, Advances in surgery.

[3]  W. Isaacs,et al.  Interleukin‐2 transfected prostate cancer cells generate a local antitumor effect in vivo , 1994, The Prostate.

[4]  F. Marshall,et al.  High efficiency gene transfer into primary human tumor explants without cell selection. , 1993, Cancer research.

[5]  R. Mulligan,et al.  The basic science of gene therapy. , 1993, Science.

[6]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Belldegrun,et al.  Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. , 1993, Journal of the National Cancer Institute.

[8]  T. Tong,et al.  Cancer statistics, 1993 , 1993, CA: a cancer journal for clinicians.

[9]  M. Tykocinski,et al.  Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. , 1993, Science.

[10]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[11]  J. Schalken,et al.  Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. , 1992, Cancer research.

[12]  E. Gilboa,et al.  Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. , 1992, Cancer research.

[13]  P. Schellhammer,et al.  Analysis of prostatic tumor cultures using fluorescence in-situ hybridization (FISH). , 1992, Cancer genetics and cytogenetics.

[14]  A. Porgador,et al.  Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. , 1992, Cancer research.

[15]  S. Rosenberg,et al.  A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability , 1992, The Journal of experimental medicine.

[16]  M. Steiner,et al.  Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. , 1992, Molecular endocrinology.

[17]  D. Pardoll,et al.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.

[18]  A. Asher,et al.  Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. , 1991, Journal of immunology.

[19]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[20]  R. Gittes.  Carcinoma of the prostate. , 1991, The New England journal of medicine.

[21]  E. Gilboa,et al.  Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. , 1990, Cancer research.

[22]  Ankita Patel,et al.  Frequency and pattern of karyotypic abnormalities in human prostate cancer. , 1990, Cancer research.

[23]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.

[24]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[25]  D. S. Coffey,et al.  The prostate: An increasing medical problem , 1990, The Prostate.

[26]  S. Miyatake,et al.  Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Chae,et al.  A simple assay for DNA transfection by incubation of the cells in culture dishes with substrates for beta-galactosidase. , 1989, BioTechniques.

[28]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[29]  R. Vessella,et al.  The value of serum prostate specific antigen determinations before and after radical prostatectomy. , 1989, The Journal of urology.

[30]  R. Mulligan,et al.  Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Beaudet,et al.  Gene transfer and gene therapy , 1988 .

[32]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[33]  H. Svanholm.  Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic specific acid phosphatase. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology.

[34]  A. Ng,et al.  Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. , 1984, American journal of clinical pathology.